Mission
BioGENext is a collaborative initiative, created as an academia-industry partnership with a mission to strengthen Ukraine’s biomedical ecosystem and unite all the society to advance next-generation therapeutics research and development.
Goal
Our aim is to create a collaborative platform, which will bring together scientists, industry leaders, educational institutions and government representatives to unite the efforts and facilitate collaborations in educational, research, development and legal projects inside Ukraine and with the global research community.
Vision
By promoting next-generation therapeutics, advancing education in biotechnology, and cultivating dialogue among key stakeholders, BioGENext aims to contribute to the formation of a robust innovation ecosystem capable of addressing both local and global healthcare challenges.
Approach
By organising focused scientific conferences, educational events, contributing to the development of educational programs and legislation initiatives and supporting various important community initiatives, bioGENext aims to contribute to the formation of a robust biomedical innovation ecosystem in Ukraine, capable of addressing both local and global healthcare challenges.
Why we initiated BioGENext
The BioGENext initiative emerged from a shared understanding of the challenges faced by academic and industrial researchers in Ukraine, and the need to empower them to advance biomedical science and stand shoulder to shoulder with the global scientific community developing next-generation therapies.
We identified several key areas that required systemic support:
Progress begins with partnership and a shared strategy
We saw an opportunity to unite efforts and address the identified needs through strong partnerships between academic and industrial laboratories and by shifting the focus of Ukraine’s innovation strategy toward biotechnology and biopharmaceutical development.
November 2023
A strategic partnership between the R&D Division of YURіA-PHARM and the Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine laid the foundation for what would become
the BioGENext initiative
The initiative began with the BioGENext Conference on Next-Generation Therapies in September 2024
— the first event of its kind in Ukraine. The conference brought together academia, industry, and government to foster collaboration and joint projects across the biomedical landscape.
It gathered over 600 participants from 25 countries
featuring talks from world-leading scientists representing institutions such as the Broad Institute of MIT and Harvard, Wellcome Sanger Institute, TU Dresden, University of Groningen, BioNTech, TRON Therapeutics, Icosagen, Cytiva, and others.
Today, two years later, BioGENext has evolved into a vibrant community of more than
1,000
Ukrainian and international researchers, uniting key universities, research institutions, and laboratory suppliers
— all contributing to the growth of Ukraine’s biomedical ecosystem.
March 2025
Launch of the BioGENext Series educational and scientific events
The BioGENext Series is primarily an educational initiative, designed to bring cutting-edge scientific knowledge directly to the biomedical research community. It focuses on sharing practical knowledge and hands-on experience in specific methods, research pipelines, and data analysis workflows that drive cutting-edge biomedical research and development.
October 2026
BioGENext Conference: Laying the Ground for a Strong Biomedical Field in Ukraine
Our scientific focuses
Nucleic-acid therapeutics: technologies and applications
Development of DNA and RNA-based therapeutic solutions, technologies for their analytics, production and delivery approaches to selectively target and alter gene expression for potential treatment of complex diseases such as cancer, infections and genetic disorders.
Recombinant proteins and MAB development technologies
Discovery, engineering and development of recombinant proteins and monoclonal antibodies to target specific molecular pathways, offering treatments for diseases, including cancer, autoimmune and metabolic disorders.
Gene editing and advanced cell technologies and applications in medicine
Discovery and engineering of effectors and their delivery approaches for the development of gene editing technologies that enable targeted modifications to DNA/RNA sequences and offer potential for treatment of genetic disorders and personalized medicine approaches.
Computational biology and AI in biomedical research
Integration of computer science and advanced AI frameworks to analyze biological data, enabling insights into complex biological systems for efficient drug discovery and personalized medicine development.
Biomarkers and molecular diagnostics
Identification and validation of specific molecules or genetic markers characteristic for certain pathological or physiological processes, and their potential application as diagnostic tools for prognosis, and treatment decisions in medicine
Other translational studies
Research activities focused on translating fundamental scientific discoveries into clinical applications, aiming to improve patient outcomes and advance medical practice.
Team
Natalia Lytvynenko
Research and Development Director, Pharmaceutical Corporation YURiA-PHARM.
Svitlana Fadieieva
PhD, Marketing Director, Hospital Marketing Directorate, YURiA-PHARM.
Mykhailo Tukalo
Member of National Academy of Sciences of Ukraine, Prof., Dr. Sci. (Mol. Biol.), Director of Institute of Molecular Biology and Genetics of National Academy of Sciences of Ukraine (IMBG NASU)
Nadiia Korotaieva
PhD, Assoc. Prof., Odesa Mechnykov National University, Scientific Communication Manager, Biotechnology products development lab, Scientific Center, YURiA-PHARM
Natalia Shenderovska
PhD, Senior Biotechnologist, Biotechnology products development lab, Scientific Center, YURiA-PHARM
Oleksandr Hubar
Head of the Biotechnology R&D Department at Pharmaceutical Corporation YURiA-PHARM
Kateryna Pohorelova (Pashchenko)
Brand manager, YURiA-PHARM
Oksana Mankovska
PhD, Senior Research Scientist, Department of Molecular Oncogenetics, IMBG NASU
Our Partners
Academ.City
Bionix Lab
BioLabTech
Biotech KAI
GMO
IMBG
IP office
KAU
NaUKMA
Yuria-Pharm
Unia Scientifica
YP biotech
ONU
KSE
KPI
KNU